Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob J-J, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou Z-Y, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2025): JCO-25-00452, doi:10.1200/jco-25-00452. ^{TOP 10%}